Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates
SUMMARY The enhanced transmissibility and immune evasion associated with emerging SARS-CoV-2 variants demands the development of next-generation vaccines capable of inducing superior protection amid a shifting pandemic landscape. Since a portion of the global population harbors some level of immunity from vaccines based on the original Wuhan-Hu-1 SARS-CoV-2 sequence or natural infection, an important question going forward is whether this immunity can be boosted by next-generation vaccines that target emerging variants while simultaneously maintaining long-term protection against existing strains. Here, we evaluated the immunogenicity of INO-4800, our synthetic DNA vaccine candidate for COVID-19 currently in clinical evaluation, and INO-4802, a next-generation DNA vaccine designed to broadly target emerging SARS-CoV-2 variants, as booster vaccines in nonhuman primates. Rhesus macaques primed over one year prior with the first-generation INO-4800 vaccine were boosted with either INO-4800 or INO-4802 in homologous or heterologous prime-boost regimens. Both boosting schedules led to an expansion of antibody responses which were characterized by improved neutralizing and ACE2 blocking activity across wild-type SARS-CoV-2 as well as multiple variants of concern. These data illustrate the durability of immunity following vaccination with INO-4800 and additionally support the use of either INO-4800 or INO-4802 in prime-boost regimens..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 25. Mai Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Walters, Jewell N. [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1101/2021.10.27.466163 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI032913605 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI032913605 | ||
| 003 | DE-627 | ||
| 005 | 20230429075520.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211030s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.10.27.466163 |2 doi | |
| 035 | |a (DE-627)XBI032913605 | ||
| 035 | |a (biorXiv)10.1101/2021.10.27.466163 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Walters, Jewell N. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a SUMMARY The enhanced transmissibility and immune evasion associated with emerging SARS-CoV-2 variants demands the development of next-generation vaccines capable of inducing superior protection amid a shifting pandemic landscape. Since a portion of the global population harbors some level of immunity from vaccines based on the original Wuhan-Hu-1 SARS-CoV-2 sequence or natural infection, an important question going forward is whether this immunity can be boosted by next-generation vaccines that target emerging variants while simultaneously maintaining long-term protection against existing strains. Here, we evaluated the immunogenicity of INO-4800, our synthetic DNA vaccine candidate for COVID-19 currently in clinical evaluation, and INO-4802, a next-generation DNA vaccine designed to broadly target emerging SARS-CoV-2 variants, as booster vaccines in nonhuman primates. Rhesus macaques primed over one year prior with the first-generation INO-4800 vaccine were boosted with either INO-4800 or INO-4802 in homologous or heterologous prime-boost regimens. Both boosting schedules led to an expansion of antibody responses which were characterized by improved neutralizing and ACE2 blocking activity across wild-type SARS-CoV-2 as well as multiple variants of concern. These data illustrate the durability of immunity following vaccination with INO-4800 and additionally support the use of either INO-4800 or INO-4802 in prime-boost regimens. | ||
| 700 | 1 | |a Schouest, Blake |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Ami |e verfasserin |4 aut | |
| 700 | 1 | |a Reuschel, Emma L. |e verfasserin |4 aut | |
| 700 | 1 | |a Schultheis, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Parzych, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Maricic, Igor |e verfasserin |4 aut | |
| 700 | 1 | |a Gary, Ebony N. |e verfasserin |4 aut | |
| 700 | 1 | |a Purwar, Mansi |e verfasserin |4 aut | |
| 700 | 1 | |a Andrade, Viviane M. |e verfasserin |4 aut | |
| 700 | 1 | |a Doan, Arthur |e verfasserin |4 aut | |
| 700 | 1 | |a Elwood, Dustin |e verfasserin |4 aut | |
| 700 | 1 | |a Eblimit, Zeena |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Frase, Drew |e verfasserin |4 aut | |
| 700 | 1 | |a Zaidi, Faraz I. |e verfasserin |4 aut | |
| 700 | 1 | |a Kulkarni, Abhijeet |e verfasserin |4 aut | |
| 700 | 1 | |a Generotti, Alison |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, J Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Humeau, Laurent M. |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos, Stephanie J. |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Trevor R.F. |e verfasserin |4 aut | |
| 700 | 1 | |a Weiner, David B. |e verfasserin |4 aut | |
| 700 | 1 | |a Broderick, Kate E. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 25. Mai |
| 773 | 1 | 8 | |g year:2022 |g day:25 |g month:05 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.vaccine.2022.03.060 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.10.27.466163 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 25 |c 05 | ||
| 953 | |2 045F |a 570 | ||